Key facts
- Atom Therapeutics’s last known valuation is $425.1M (Aug 2025).
- It has raised $70.0M; the latest was IPO in Sep 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, HSG (Hong Kong), Fortune Capital, Shenzhen Yifeng Investment Management Enterprise, Heda Ventures — 15 tracked in total.
- Status: In IPO Registration.
Investors
15+- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Atom Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Atom Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Atom Therapeutics
Developer and researcher of new drugs and treatments designed to treat metabolic diseases and cancers. The company's treatments focus on the field of metabolism and inflammation, which includes Non-Alcoholic SteatoHepatitis (NASH), gout, diabetes and colon cancers, providing patients with more effective medication and treatments for cancer and metabolic diseases.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2012
- Employees
- 60
- Website
- atomthera.us/
- Ownership
- In IPO Registration
Atom Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Atom Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Atom Therapeutics in its N-PORT filings yet. We sweep new filings monthly.